MedTrace Logo

A Study of SPY002-091 in Healthy Volunteers

NCT06672718 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-08-17

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

SPY002-091

Experimental

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Altasciences Company Inc.

    collaborator INDUSTRY

  • Spyre Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Joshua Friedman, MD · Spyre Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2026-02-18
Completion
2026-06-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672718 on ClinicalTrials.gov